News

Stay Updated! In The World Of Investments!
Sensex 48544.06 660.68 (1.38%)

Orchid Pharma Latest News

15

Jan, 2021

Orchid Pharma informs about disclosure

In accordance with Regulation 31A(8)(c) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Orchid Pharma has informed the Company has submitted the applica...

Read More

01

Jan, 2021

Orchid Pharma informs about outcome of 27th AGM

Orchid Pharma has informed that the 27th Annual General Meeting (AGM) of the Company was held on December 30, 2020 at 12:00 Noon through Video conference (VC)/ Other Audio Visual Means (OAVM). In this regard, the Co...

Read More

08

Apr, 2020

Orchid Pharma informs about disclosure

Orchid Pharma has informed that the Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dhanuka Laboratories.

T...

Read More

06

Mar, 2020

Orchid Pharma informs about appointment of CS cum CO

Orchid Pharma has informed that pursuant to Regulation 30 and other applicable regulations of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, Nikita. K (Membership No: AS56938) has bee...

Read More

19

Nov, 2019

NCLAT rejects bid of Dhanuka Laboratories for debt ridden Orchid Pharma

National Company Law Appellate Tribunal (NCLAT) has rejected the bid of Dhanuka Laboratories for the debt ridden Orchid Pharma, and vacated the order passed by the Chennai-bench of National Company Law Tribunal (NCL...

Read More

15

May, 2019

Orchid Pharma shines on getting nod from USFDA for Risedronate Sodium Tablets

Orchid Pharma is currently trading at Rs. 4.00, up by 0.17 points or 4.44% from its previous closing of Rs. 3.83 on the BSE.

The scrip opened at Rs. 4.00 and has...

Read More

14

May, 2019

Orchid Pharma gets nod from USFDA for Risedronate Sodium Tablets

Orchid Pharma has received ANDA approval from United States Food and Drug Administration (USFDA) for Risedronate Sodium Tablets USP, 30 mg and 35 mg. Risedronate sodium tablets are a bisphosphonate indicated for the...

Read More

24

Nov, 2018

Orchid Pharma informs about board meeting

Orchid Pharma has informed that the meeting of the Board of Directors of the Company is scheduled on 30/11/2018, to consider and approve the unaudited financial results for the quarter ended june 30,2018.

Read More

21

Nov, 2018

Orchid Pharma informs about AGM

In accordance with the requirements of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Orchid Pharma has informed that the Twenty Fifth Annual General Meeting (AGM) of the company has been proposed...

Read More

21

Nov, 2018

Orchid Pharma informs about newspaper publication

In accordance with the requirements of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Orchid Pharma has informed about submission of copies of the advertisement of the notice of the 25th Annual Ge...

Read More

Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback